Targeting connexin 43 protects against the progression of experimental chronic kidney disease in mice by A. Abed et al.
Targeting connexin 43 protects against the
progression of experimental chronic kidney disease
in mice
Ahmed Abed1,2,5, Julie Toubas1,2,5, Panagiotis Kavvadas1, Florence Authier1, Dominique Cathelin1,
Carlo Alfieri1,6, Jean-Jacques Boffa1,2,3, Jean-Claude Dussaule1,2,4, Christos Chatziantoniou1,2 and
Christos E. Chadjichristos1,2
1INSERM UMR-S1155, Tenon Hospital, Paris, France; 2Sorbonne Universite´s, UPMC Univ Paris 6, Paris, France; 3Department of
Nephrology, Tenon Hospital, Paris, France and 4Department of Physiology, Saint-Antoine Hospital, Paris, France
Excessive recruitment of monocytes and progression of
fibrosis are hallmarks of chronic kidney disease (CKD).
Recently we reported that the expression of connexin 43
(Cx43) was upregulated in the kidney during experimental
nephropathy. To investigate the role of Cx43 in the
progression of CKD, we interbred RenTg mice, a genetic
model of hypertension-induced CKD, with Cx43þ / mice.
The renal cortex of 5-month-old RenTgCx43þ / mice
showed a marked decrease of cell adhesion markers leading
to reduced monocyte infiltration and interstitial renal fibrosis
compared with their littermates. In addition, functional
and histological parameters such as albuminuria and
glomerulosclerosis were ameliorated in RenTgCx43þ /
mice. Interestingly, treatment with Cx43 antisense produced
remarkable improvement of renal function and structure
in 1-year-old RenTg mice. Similar results were found in
Cx43þ / or wild-type mice treated with Cx43 antisense after
obstructive nephropathy. Furthermore, in these mice, Cx43
antisense attenuated E-cadherin downregulation and
phosphorylation of the transcription factor Sp1 by the ERK
pathway resulting in decreased transcription of type I collagen
gene. Interestingly, Cx43-specific blocking peptide inhibited
monocyte adhesion in activated endothelium and profibrotic
pathways in tubular cells. Cx43 was highly increased in
biopsies of patients with CKD. Thus, Cx43 may represent a
new therapeutic target against the progression of CKD.
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The number of patients suffering from CKD is growing
worldwide because of aging of the population, improved
survival from cardiovascular diseases, and spreading of
type-2 diabetes. CKD is characterized by chronic inflamma-
tion leading to abnormal accumulation of extracellular
matrix components (mainly collagens type I and III) and
structural alterations within all renal compartments.1,2 Thus,
arresting or reversing the progression of renal disease repre-
sents one of the major challenges in public health and there is
an urgent need to identify new targets of therapy.
Recruitment of leukocytes from the blood to the injured
site is an important step in the inflammatory cascade, and
gap junctions (GJs) are highly implicated in this process.3,4
GJ channels are formed by the multimeric assembly of
connexins (Cxs), being specialized in the control of direct
exchange of small metabolites between adjacent cells. To date,
over 20 Cx isoforms have been characterized in mammalian
cells.5,6 One GJ channel results from the docking of two
hemichannels or connexons. Each connexon is assembled
from six Cx proteins and can open under both physiological
and pathological conditions. Connexons and GJ channels
may be formed by different Cxs.7,8 Each type of Cx-made
channel has unique inherent gating properties or permeabi-
lities to various molecules and ions. Thus, the Cx composi-
tion of GJ channels appeared to determine selectivity for
different second messengers.9
We have previously reported that Cxs are able to regulate
monocyte adhesion in chronic vascular inflammatory
diseases.10,11 We have also recently demonstrated that Cx43
expression was increased in the early stages of hypertension-
induced and obstructive nephropathy in the renal cortex of
the diseased mice. The Cx43 upregulation was paralleled
closely by that of cell adhesion molecules, indicating that this
Cx may be considered an early signal of renal inflammation
during the progression of CKD.12 In the present study we
investigated whether targeting Cx43 expression by genetic
and pharmacogenetic manipulation could alter the progres-
sion of renal disease. First, we generated a double transgenic
strain by crossbreeding RenTg mice, a genetic model of
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hypertension-induced CKD, with mice in which Cx43
expression was genetically reduced by half (Cx43þ / ). In
addition, we used Cx43þ / to perform unilateral ureteral
obstruction (UUO), another model of CKD in which the
initiating cause is tubulointerstitial inflammation. Finally, we
inhibited the Cx43 upregulation in wild-type (WT) mice by
delivering an oligodeoxynucleotide antisense (AS) in the two
above-mentioned models of experimental nephropathy. Our
results demonstrate for the first time that reduction of Cx43
expression limited inflammatory cell infiltration as well as
renal fibrosis and markedly improved renal structure and
function, indicating that this protein may represent a new
therapeutic target against the progression of CKD.
RESULTS
Decreased Cx43 expression ameliorates renal structure and
prevents the decline of renal function in hypertension-
induced CKD
We have previously demonstrated that Cx43 expression
is increased in RenTg mice since the early stages of the
disease.12 In addition, immunofluorescence showed that
Cx43 was strongly increased within injured kidneys during
the progression of disease (Supplementary Figure S1 online).
To obtain further insight into the implication of Cx43 in
hypertension-induced CKD, we first attempted to inhibit the
Cx43 upregulation in these mice. Given that the Cx43
knockout mouse dies shortly after birth,13 we interbred
RenTg with Cx43þ / to generate RenTgCx43þ / mice.
As the role of Cx43 in the modulation of blood pressure
is controversial,14–16 we first compared arterial pressure
between RenTgCx43þ / , RenTgCx43þ /þ , and WT
mice aged 5 months (mo). Systolic blood pressure was
significantly increased in hypertensive mice compared with
WT controls (Figure 1a). However, decreasing expression of
Cx43 did not modulate systolic blood pressure (150±6.5mm
Hg in RenTgCx43þ /þ and 152±6.1mmHg in
RenTgCx43þ / ). Therefore, phenotypic observations due
to the genetic deletion of Cx43 are independent from blood
pressure. In addition, we confirmed the overexpression of
Cx43 messenger RNA (mRNA) in RenTgCx43þ /þ mice
compared with WT healthy animals. This upregulation was
blunted in 5-mo-old RenTgCx43þ / mice (Figure 1b).
Next, we checked whether decreased expression of Cx43
could affect the renal structure. Masson’s trichrome staining
showed that 5-mo-old RenTgCx43þ /þ mice presented
established lesions typical of hypertension-induced CKD,
such as perivascular and periglomerular inflammation,
glomerular ischemia, glomerulosclerosis, and tubular dila-
tion, compared with WT healthy animals (Figure 1c). In
RenTgCx43þ / mice the renal structure was preserved, as
glomerulosclerosis and tubular dilation were significantly
decreased (Figure 1d and e, respectively) and consequently
microalbuminuria was highly reduced (Figure 1f). Thus,
decreased expression of Cx43 was associated with improved
renal structure and function during the progression of
hypertension-induced CKD.
Next, we investigated at the same time point the relation
between decreased Cx43 expression and inflammation during
the progression of the disease. Quantitative PCR showed that
mRNA expression for C-C chemokine receptor type 2 and
vascular adhesion molecule-1 (VCAM-1) was highly upregu-
lated in RenTgCx43þ /þ mice compared with WT healthy
animals (Figure 2a and b, respectively). In RenTgCx43þ /
this increase was significantly restricted. In addition, F4-80
immunostaining showed a pronounced inflammatory cell
infiltration in cortical slices of RenTgCx43þ /þ mice
(Figure 2c). In contrast, monocyte recruitment was highly
reduced in RenTgCx43þ / animals (Figure 2d). To explore
whether Cx43 could control the leukocyte recruitment,
we compared adhesion of the RenTgCx43þ /þ and
RenTgCx43þ / monocytes collected after peritoneal lavage
with an activated mouse endothelial cell monolayer. As
shown in Figure 2e, the number of adherent Cx43-deficient
monocytes was considerably reduced. Thus, reduced Cx43
expression leads to restricted interstitial inflammation during
the progression of hypertension-induced CKD.
Given that Cx43 downregulation limited monocyte
infiltration, we hypothesized that this protein may influence
the development of renal fibrosis. As expected, quantitative
PCR showed a marked upregulation of the mRNAs of
transforming growth factor-b1 (TGF-b1) and type I collagen
(Col1) in RenTgCx43þ /þ mice. This upregulation was
blunted in the RenTgCx43þ / animals (Figure 2f and g,
respectively). In accordance, Sirius Red coloration demon-
strated a decreased interstitial collagen deposition in the
cortex of RenTgCx43þ / mice (Figure 2h). We can thus
conclude that Cx43 contributes to interstitial renal fibrosis in
addition to monocyte infiltration during the progression of
hypertension-induced CKD.
Targeting Cx43 protects against the progression of
hypertension-induced CKD
To investigate whether Cx43 could be a potential therapeutic
target against the progression of CKD, we blocked its over-
expression by using Cx43AS, known to specifically decrease
Cx43 expression.17–20 This AS was administered to 11-mo-old
RenTg mice, suffering thus from advanced hypertension-
induced CKD, for 1 mo via minipump infusion. Scrambled
(SCR) sequence was used as control. As illustrated in
Figure 3a, Masson’s trichrome showed that the renal structure
of 1-year-old RenTg mice treated with SCR was considerably
damaged. In contrast, RenTg mice treated with Cx43AS
showed a substantial improvement in renal structure as
glomerulosclerosis and tubular dilation were significantly
reduced (Figure 3b and c, respectively). Consequently, CKD
progression was hindered as renal function was highly
ameliorated (Figure 3d). In addition, decreased expression
of Cx43 (Figure 3e) led to a lesser upregulation of VCAM-1 at
both mRNA (Figure 3f) and protein levels (Supplementary
Figure S2 online), and consequently limited monocyte
infiltration (Figure 3g). Furthermore, upregulation of col1
and TGF-b1 mRNA levels was blunted in RenTg animals
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following AS infusion (Figure 3h and i, respectively) and
consequently interstitial fibrosis was also reduced (Figure 3j).
These data suggest that Cx43 may be used as a therapeutic
target against the progression of hypertension-induced CKD.
Decreased Cx43 expression reduces monocyte infiltration
and interstitial fibrosis following obstructive nephropathy
Increased expression of Cx43 was also observed during the
progression of obstructive nephropathy within injured
kidneys in WT mice (Supplementary Figure S3 online). To
investigate whether the potential protective effect of Cx43
blockade is not model dependent, Cx43þ / and their
littermates underwent UUO and were euthanized after 7 and
15 days (d). Cx43 mRNA upregulation was confirmed 7d
after UUO (Figure 4a), and as expected an increased
expression of the mRNA of VCAM-1 (b), P-selectin (c),
and chemokine receptor type 2 (d) was also observed. In
contrast, at the same time point this upregulation was signifi-
cantly reduced in Cx43þ / mice. As monocytes have a
major role in the inflammatory process in this model of renal
nephropathy,21 we next performed F4-80 immunostaining.
An important macrophage infiltration was detected in the
interstitium of the obstructed kidneys 7d after UUO, whereas
in Cx43þ / mice the infiltrate was significantly reduced
(Figure 4e). Next, we studied the impact of the Cx43 deletion
on the progression of interstitial renal fibrosis 15d after UUO.
We observed that Col1 and Col3 mRNA levels increased
significantly after UUO compared with the levels in the
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Figure 1 | Decreased expression of connexin 43 (Cx43) improves renal structure and function during the progression of hypertension-
induced chronic kidney disease (CKD). Measurements of systolic blood pressure (SBP) in RenTgCx43þ /þ and RenTgCx43þ / mice
indicate that decreased Cx43 expression did not modulate blood pressure values (a). Quantitative PCR (qPCR) analysis in the renal cortex
showed a marked increase in Cx43 messenger RNA (mRNA) expression in RenTg mice aged 5 months (mo) compared with normotensive
wild-type (WT) mice. Cx43 upregulation was blunted in RenTgCx43þ / mice (b). Representative examples of renal cortical histology
revealed by Masson’s trichrome in 5-mo-old WT, RenTgCx43þ /þ , and RenTgCx43þ / mice. Note the substantial improvement in the
renal histology in RenTgCx43þ / mice (c). Renal parameters such as glomerulosclerosis (d), tubular dilation (e), and proteinuria (f) were
significantly ameliorated in these mice (n¼ 9 mice from each group; *Po0.05, **Po0.01, ***Po0.001; original magnification of
microphotographs 200).
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contralateral nonobstructive kidneys (Figure 4g and h,
respectively). However, upregulation of mRNA expression
of both collagens was blunted in Cx43þ / and the accu-
mulation of interstitial collagen formation was also reduced
(Figure 4i). Furthermore, immunostaining for fibroblast-
specific protein-1, a well-established fibrotic marker, showed
limited fibroblast-specific protein-1-positive cells after UUO
in Cx43þ / mice (Supplementary Figure S4 online).
In conclusion, similar to hypertension-induced nephropathy,
decreased expression of Cx43 limited the inflammatory
reaction and decreased excessive extracellular matrix accu-
mulation, leading to improved renal structure.
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Figure 2 | Reduced connexin 43 (Cx43) expression limits inflammation and interstitial renal fibrosis during the progression of
hypertension-induced chronic kidney disease (CKD). Quantitative PCR (qPCR) in the renal cortex showed that in 5-month (mo)-old
RenTgCx43þ / mice messenger RNA (mRNA) expression of chemokine receptor type 2 (CCR-2) (a) and vascular adhesion molecule-1
(VCAM-1) (b) was significantly inhibited, compared with RenTgCx43þ /þ littermates. F4-80 immunostaining showed that macrophage
infiltration was considerably restricted in RenTgCx43þ / mice (c). Histogram shows quantification of the F4-80 macrophage–specific signal (d).
Adhesion of RenTgCx43þ / monocytes to an activated endothelial layer was highly decreased compared with RenTgCx43þ /þ control
ones (e). Upregulation of transforming growth factor-b1 (TGF-b1) (f) and col1 (g) mRNA expressions was decreased in RenTgCx43þ / mice.
In accordance, Sirius red coloration showed restricted renal interstitial fibrosis in RenTgCx43þ / mice (h) (n¼ 9 mice from each group;
*Po0.05, **Po0.01, ***Po0.001; original magnification of microphotographs 200).
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Figure 3 | Targeting connexin 43 (Cx43) upregulation with Cx43-ODN antisense (AS) improves renal structure and function during the
progression of hypertension-induced chronic kidney disease (CKD). Representative examples of renal cortical histology revealed by
Masson’s trichrome in 1-year-old wild-type (WT), RenTg scrambled (SCR), and RenTgCx43AS mice (a). Note the substantial improvement in renal
histology in RenTg mice that received Cx43AS for 1 month (mo) via minipump infusion. Glomerulosclerosis (b), tubular dilation (c), and
proteinuria (d) were also significantly decreased in hypertensive mice that received Cx43-ODN AS (10 mmol/l). Quantitative PCR (qPCR) analysis
in the renal cortex showed that upregulation of Cx43 (e) and vascular adhesion molecule-1 (VCAM-1) (f) messenger RNAs (mRNAs) was
blunted in RenTg mice after AS administration. Quantification of the F4-80 macrophage–specific signal (g). In addition, mRNA expression of
col1 (h) and transforming growth factor-b1 (TGF-b1) (i) as well as interstitial renal fibrosis (j) was also significantly decreased in mice after
Cx43-ODN AS infusion (n¼ 7 mice per group; *Po0.05, **Po0.01, ***Po0.001; original magnification of microphotographs 200).
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Targeting Cx43 improves renal structure after UUO
To confirm the protective effect of the Cx43-decreased
expression after UUO, we injected a Cx43-ODN AS or a
SCR sequence locally in the dilated ureter 24 h after obstruc-
tion. Mice were killed 7d after UUO. To quantify the extent of
Cx43 knockdown after the AS administration, we assessed
Cx43 expression by quantitative PCR. As shown in Figure 5a,
the upregulation of the Cx43 mRNA expression was atte-
nuated after the AS injection. In addition, we observed a
marked decrease in the VCAM-1 mRNA and protein
expressions in the obstructed kidneys that received Cx43AS
compared with those that received SCR after UUO (Figure 5b
and c, respectively). Interestingly, western blotting for
E-cadherin, a marker of renal tubular epithelial phenotype,
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Figure 4 | Connexin 43 (Cx43) heterozygous mice show limited inflammation and fibrosis following obstructive nephropathy.
Quantitative PCR (qPCR) analysis in the renal cortex showed that Cx43 messenger RNA (mRNA) upregulation was blunted in Cx43þ / mice
7 days (d) after unilateral ureteral obstruction (UUO; a). Decreased expression of Cx43 significantly inhibited mRNA expression of vascular
adhesion molecule-1 (VCAM-1) (b), P-selectin (c), and chemokine receptor type 2 (CCR-2) (d). Macrophage infiltration was considerably
restricted in Cx43þ / mice (e). Histogram shows quantification of the F4-80 macrophage staining 7d after UUO (f). Fifteen days after UUO,
upregulation of col1 (g) and col3 (h) mRNA expressions was blunted in Cx43þ / mice. Quantification of Sirius red coloration by
morphometric analysis showed restricted renal interstitial fibrosis in Cx43þ / mice (i) (n¼ 10 mice per group, *Po0.05, **Po0.01,
***Po0.001; original magnification of microphotographs 200).
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showed that its expression was partially restored after AS
treatment, indicating an improvement in the renal structure.
In accordance, macrophage infiltration was clearly decreased
in Cx43AS-treated kidneys (Figure 5f and g). As previously
observed, limitation of cell infiltration at the injured site
resulted in restricted interstitial fibrosis. Given that GJs are
implicated in pathways regulating the transcription of the
target genes, we speculated that signaling passing through the
Cx43 channels could affect the expression of the col1 gene
after UUO. We focused directly on the extracellular signal-
regulated kinase (ERK) signaling pathway that has been
shown to regulate the phosphorylation and transcriptional
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activity of Sp1, known to be a powerful activator of the
transcription of the col1 gene.22,23 Mice that received SCR
sequence after UUO had a pronounced activation of the ERK
activity as the phosphorylation of ERK was highly increased
(Figure 6a and b). The phosphorylated form of the Sp1
transcription factor was also markedly increased (Figure 6a
and c). At the same time point, the expression of col1 mRNA
was increased by almost 50-fold. In contrast, local treatment
with Cx43AS reduced the phosphorylation of ERK by half
and abolished the phosphorylation of Sp1, leading to a
significant reduction in col1 mRNA expression (Figure 6d).
Furthermore, Cx43AS significantly reduced mRNA expres-
sion of TGF-b1, one of the most important profibrotic cyto-
kines in renal damage (Figure 6e). These data demonstrate
that decreasing the Cx43 expression limited the inflammatory
process and restricted interstitial renal fibrosis and thus
resulted in renal structure preservation.
Cx43-specific blocking peptide inhibits monocyte adhesion
as well as profibrotic pathways in renal tubular cells
In the above-mentioned models of CKD, Cx43 seemed to
participate in two essential processes during the progression
of the disease: monocyte recruitment and tissue fibrosis. To
assess the functional importance of Cx43, we used Gap26
peptide, a Cx43-specific GJ blocker that inhibits the docking
of the Cx43 hemichannels and consequently the Cx43-
mediated GJ intercellular communication (GJIC).17 As
shown in Supplementary Figure S5A online, the number of
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Figure 6 | Connexin 43 (Cx43)-ODN antisense (AS) decreased fibrotic pathways in obstructed kidneys of wild-type (WT) mice.
Representative western blotting experiments for P-extracellular signal-regulated kinase (ERK), ERK, Sp1, and GAPDH were performed by using
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monocytes that adhere to an activated mouse endothelial cell
monolayer previously incubated with Gap26 was significantly
reduced. In addition, freshly extracted monocytes incubated
with Gap26 showed considerably less adhesion to the
activated bEnd3 monolayer. These data showed that Cx43
expression may have a proadhesive role mainly in monocytes
and to a lesser extent in activated endothelial cells.
To study the functional importance of Cx43 in profibrotic
pathways we first incubated mouse tubular cells (mCCDs)
with TGF-b1. This stimulation led to de novo expression of
Cx43 mainly between the neighboring cells (Supplementary
Figure S5B online). Furthermore, incubation of tubular cells
with Gap26 inhibited the TGF-b1-induced ERK pathway
(Supplementary Figure S5C and D online), the phosphoryla-
tion of the transcription factor Sp1, and the upregulation of
col1 (Supplementary Figure S5E and F online, respectively).
Thus, Cx43 may participate in the profibrotic effects of
TGF-b1 through the exchange of second messengers passing
through the Cx43 channels.
DISCUSSION
Impairment of GJIC has been reported to have a large impact
on various diseases.4 In this study we demonstrated for the
first time that Cx43 upregulation contributes to structural
damages within the renal cortex during the progression of
renal disease, and inhibiting its expression improved tissue
structure and function.
To investigate whether Cx43 could be a key mediator of
renal disease, we took advantage of two different mouse
models of CKD. The first, the RenTg model, has been recently
described as a powerful tool for studying CKD as it presents
all physiopathological characteristics of a slowly progressive
hypertension-induced renal disease.24 The second, the UUO,
is a well-established model of tubulointerstitial renal disease
leading to renal fibrosis.25 Although these two experimental
models target distinct renal compartments, they are linked by
their ability to promote development of chronic inflammation
and fibrosis leading to severe damages to the renal structure.
In both models we showed that Cx43 expression was
increased during the progression of renal disease (Supple-
mentary Figure S1 and S3 online) and that decreased Cx43
expression was beneficial in chronic inflammation. This
process requires cross-talks between leukocytes and the
injured tissue and a high level of coordination in which GJs
are involved. It has been reported that in various stages of
inflammatory diseases Cx43 expression and distribution can
markedly change, thus modulating the progression of the
injury.3,26,27 Indeed, in chronic models of inflammation in
mice, such as atherosclerosis, an upregulation of Cx43 by the
dysfunctional vascular endothelium was detected in the
shoulder of the lesions, as well as in intimal smooth muscle
cells at the early stages of the disease.28 Similar temporal
expression patterns of Cx43 were also observed in rodents, in
the muscular microcirculation following inflammatory
stimulation, in obstructed kidneys, and in myocardial
endothelial–mesenchymal transition.29–31 In addition, it has
been reported that Cx43 expression was enhanced in damaged
tubules and interstitial cells in human kidneys and in rat
podocytes in puromycin aminonucleoside nephrosis.32,33 The
Cx43þ / mouse has been used in several diseases to
investigate the link between Cx43 and inflammation. Thus, in
accordance with our study, in LDLR (low-density lipoprotein
receptor)–deficient mice with reduced Cx43 levels,
atherogenesis was markedly inhibited and the composition
of the atherosclerotic plaques exhibited reduced amount of
leukocytes.34 Additional studies in the same model showed
limited local monocyte infiltration leading to faster repair and
re-endotheliazation following acute vessel injury.11 Cx43þ /
mice also displayed blunted neutrophil recruitment in vivo
in an acute lung injury model after instillation of
lipopolysaccharide.26 Interestingly, the authors of this study
used mice harboring heterozygous expression of a C-terminal
truncation of Cx43, thus creating GJ channels unable to
response to chemical stimuli.35,36 These mice showed
enhanced recruitment of neutrophils to the airways and
mortality in response to lipopolysaccharide.26 The role of
endothelial Cx43 has also been studied using endothelial-
specific Cx43-null mice (Cx43e / ). Thus, Cx43e /
mice and blockade of GJIC by chemical inhibitors showed
reduced leukocyte adhesion and transmigration upon tumor
necrosis factor-a stimulation in the hamster cheek pouch.29 All
these studies point out the crucial role of Cx43 in the inflam-
matory response in various tissues. The exact molecular
mechanisms involving this Cx in the recruitment of inflam-
matory cells at the site of injury are poorly understood. Recent
studies suggested that Cx43 channels may serve as conduits for
spreading proinflammatory signals within the endothelial
network. Indeed, propagation of Ca2þ waves between
endothelial lung capillaries through Cx43 channels activated
the expression of the leukocyte adherence receptor P-selectin,
after intratracheal administration of lipopolysaccharide.
Furthermore, peptide inhibitors for Cx43 completely blocked
the thrombin-induced microvascular permeability.37 Accor-
dingly, decreased expression of Cx43 in our experimental
models blunted the upregulation of cell adhesion molecules
and consequently monocyte adhesion within the injured
kidneys. In addition, functional assays using a Cx43-blocking
peptide in activated endothelial cells and monocytes showed
that Cx43 has a major role in both monocyte adhesion and
endothelial cell activation. Interestingly, it seemed that
Cx43 GJIC has a proadhesive role mainly in monocytes and
to a lesser extent in the endothelial cell activation at least
in vitro. However, we cannot underestimate the importance
of the renal-activated endothelium during the progression of
CKD in vivo.
Extracellular matrix remodeling is a dynamic process that
occurs in response to inflammation. As we observed that
decreased Cx43 limited leukocyte adherent receptors and
infiltration, we hypothesized that this protein may modulate
renal fibrosis during the progression of CKD. We showed that
in Cx43þ / mice interstitial collagen deposition was
reduced in comparison with Cx43 WT animals. It has been
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reported that Cx43 can regulate profibrotic marker expres-
sion such as TGF-b and vice versa, as well as collagen
deposition.38–40 However, in contrast to the inflammatory
process, the role of Cx43 in tissue sclerosis is controversial.
Our results are in accordance with those of Zhang et al.,41
who demonstrated that reduced expression of Cx43 inhibited
collagen content, thus attenuating ventricular remodeling
after myocardial infarction. Moreover, TGF-b was highly
upregulated in myocardial infarction hearts but its phos-
phorylated mediator, pSmad, was markedly decreased in the
nuclei of Cx43þ / hearts after myocardial infarction in
mice. Interestingly, it has been shown that Cx43 served as a
positive regulator of the TGF-b/Smad signaling pathway in
mouse cardiomyocytes.42 The ability of GJIC to modulate
signaling affecting the transcription of profibrotic genes has
been well documented in bone biology. Indeed, Cx43 GJ
between osteoblasts permits the intercellular propagation of
second messengers that activate the ERK signal cascades.
These signals regulated the recruitment of the transactivator
Sp1 to a Cx-responsive element in the promoter, leading to a
robust transcription of the type I collagen gene. When the
GJIC was disrupted, the collagen transcription was decreased
because of diminished propagated signals among cells.40
A similar situation may occur during the progression of
renal interstitial fibrosis following obstructive nephropathy.
Indeed, the blockade of Cx43 upregulation inhibited the
phosphorylation of Sp1 via the ERK pathway, resulting in
decreased transcription of the type I collagen gene. Similarly,
in vitro experiments in renal tubular cells confirmed our
hypothesis that Cx43 may participate in the profibrotic
effects of TGF-b1 via exchange of second messengers passing
through the Cx43 channels. Another argument reinforcing
our hypothesis that Cx43 participates in the progression of
renal fibrosis in CKD is that Cx43þ / mice showed a
restricted number of fibroblast-specific protein-1-positive
cells. In contrast, Cx43þ / LDLR / mice presented more
collagen deposits within atherosclerotic plaques.28 Moreover,
knocking down Cx43 in a wound-healing model in the skin
resulted in increased mRNA for TGF-b1 and collagen content
at the wound site.43 These differences in terms of collagen
deposition may reflect different cellular adaptive processes
during matrix remodeling and wound healing.
An additional novel finding of our study is the demon-
stration that Cx43 is a possible pharmacological target
against inflammation and renal fibrosis. The Cx43 blockade
considerably improved glomerular injury and renal failure in
hypertension-induced CKD and tubular injury after UUO.
Moreover, administration of Cx43AS as a therapeutic
approach in RenTg mice suffering from an advanced stage
of renal disease blunted CKD progression as renal structure
and function were close to that of healthy mice. Thus, the
protective effects of the Cx43 blockade in different models of
experimental nephropathy suggest the involvement of this Cx
in common pathophysiological mechanisms associated with
the development of renal disease. To our knowledge, curative
treatment of mice with AS is the first pharmacological
attempt to transiently block Cx43 activity in vivo in the
context of CKD. Similar to our results, Mori et al.43 showed
that recruitment of both neutrophils and macrophages was
markedly reduced within Cx43AS-treated wounds. This study
suggests that reducing Cx43 expression early in the skin
enhanced the wound-healing process because of inflamma-
tory response attenuation. In addition, blocking Cx43
upregulation in different models of spinal cord injury and
in corneal scrape injury in rats reduced inflammation and
improved functional recovery.19,20 Finally, in a rat model of
collagen-induced arthritis, silencing the expression of Cx43
by short interfering RNA decreased inflammation and joint
destruction.44 All these studies underline the interest for
targeting specifically Cx43 to protect against the progression
of inflammatory diseases.
The interest to develop Cx43 pharmacological inhibitors
in CKD is reinforced by the exaggerated expression of this
protein in patients with nephroangiosclerosis or obstructive
nephritis in comparison with healthy controls (Figure 7).
These results are in accordance with the study by Hillis et al.32
who reported an upregulation and colocalization of Cx43 and
a b
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Figure 7 | Connexin 43 (Cx43) immunostaining in human renal
biopsies. Cx43 expression is weak in the renal cortex of control
kidneys (a). Cx43 immunofluorescence (in green) is markedly
increased in patients suffering from nephroangiosclerosis (b) and
obstructive nephritis (c). Cx43 expression highly increased in severe
nephroangiosclerosis (d–f). Cryosections were counterstained with
Evans blue (red) and nuclei were stained with 4’,6-diamidino-2-
phenylindole (DAPI; blue). Original magnification of
microphotographs 400.
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cell adhesion molecules in human renal biopsies of patients
suffering from inflammatory renal diseases. In addition, the
expression pattern of Cx43 in humans and in mice suffering
from CKD looks rather similar (Supplementary Figure S1
and S3 online). Our data suggest that Cx43 overexpression in
the damaged compartment leads to propagated proinflam-
matory and profibrotic signals within the whole renal tissue.
Thus, as the disease progresses throughout the neighboring
renal compartments, Cx43 may be expressed by all cell types
affected by the disease. In agreement with this assumption,
we have observed that in biopsies from renal pathologies, as
well as in injured renal tissues in mice, Cx43 is always
expressed in proximity to damaged areas.
In summary, we demonstrated that Cx43 has a key role in
CKD. Its overexpression in the damaged compartments in
response to the injury participates in the progression of renal
disease. Thus, Cxs may represent a pertinent therapeutic
target and knocking down Cx43 could have widespread
applications in renal diseases in improving the structure and
function of the injured kidneys.
MATERIALS AND METHODS
Animals
All mice were kept in well-controlled animal housing facilities and
had free access to tap water and pellet food. All protocols have been
approved by the French Institutional Committee (INSERM and the
University ‘Paris VI’). Detailed methods of all the in vivo experi-
mental procedures can be found in Supplementary Material online.
Renal morphology and immunohistochemistry
Kidneys were fixed in formalin solution (4%) and embedded in
paraffin after conventional processing. Sections (3mm thick) were
stained with Masson’s trichrome for evaluation of renal damage.
Interstitial fibrosis was assessed on Sirius red–stained paraffin
sections. All measurements were taken in a blinded manner on
coded slides. Measurements of proteinuria were taken as previously
described.24 Immunostaining was performed on paraffin-embedded
sections and on cryosections of renal biopsies from patients
suffering from renal diseases. Negative controls included omission
of first antibodies or preincubation of first antibodies with
immunogenic peptides. Detailed methods of all the procedures
can be found in Supplementary Material online.
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